B2RLaw advised Life Science Innovation Fund on its investment in a healthtech startup

B2RLaw has advised the Life Science Innovation Fund on its investment in AIDLAB, a telemedical startup. The aim of the investment is to develop a new product, AIDMED, a device which remotely diagnoses diseases, particularly sleep breathing and cardiac disorders.

The healthtech industry is experiencing noticeable growth during the current pandemic. Innovative solutions that allow certain activities to be performed remotely are relieving the burden on medical personnel while providing more comfortable conditions for patients. AIDMED’s solutions can reduce hospitalization periods to a minimum using artificial intelligence to analyze measurements.

The investor is a Polish VC, Life Science Innovation Fund, which invests in MedTech, Biotech and Health Care, and has invested in a number of successful companies such as BrainScan, Bioseco, LumiSep and LifeFlow.

B2RLaw’s consisted of Partner Szymon Syp, Ph.D. and Senior Associate Iga Wojtczak-Opala.